FDA Orange Book Therapeutic Equivalence Codes Explained

The FDA Orange Book lists approved drug products and therapeutic equivalence evaluations. An A code generally indicates FDA considers a product therapeutically equivalent to the reference within the coded product group; a B code indicates FDA has not determined equivalence. The code supports professional decision-making but does not itself replace state substitution law, the prescription, or pharmacist judgment.

What the Orange Book is

The Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, is FDA’s reference for approved drug products and certain patent and exclusivity information. Its therapeutic equivalence evaluations help compare multisource prescription products. A technician may encounter a product’s rating while researching a generic or answering a stock question, but the rating is only one part of the decision to dispense a particular product.

Therapeutic equivalence has defined criteria

FDA’s concept of therapeutic equivalence applies to products with the identical active ingredient(s), not different medicines used for the same condition. Products generally must be approved as safe and effective, be pharmaceutical equivalents, demonstrate bioequivalence as applicable, be adequately labeled, and be manufactured under current good manufacturing practice. Pharmaceutical equivalents have the same active drug ingredient, dosage form, route, and amount, though inactive ingredients and some product characteristics can differ.

Reading the first letter

The first character broadly separates A-rated products, which FDA considers therapeutically equivalent to pharmaceutically equivalent products, from B-rated products for which actual or potential bioequivalence concerns have not been resolved or FDA lacks a basis for that conclusion. A second letter or additional number provides more detail about the dosage form or reference product relationship. The exact code definitions are in the Orange Book preface. Do not memorize “A means always interchangeable” as an absolute rule.

What AB means

An AB rating generally means the multisource product has met necessary bioequivalence requirements relative to a reference listed drug within the relevant product grouping. FDA notes that products must be compared within the same heading, active ingredient, dosage form and route, and same strength. Some products receive three-character codes such as AB1 or AB2 when multiple reference listed drugs are present. Products with different AB numbers may not be interchangeable with each other just because both start with AB.

Why dosage form and release matter

A tablet and an oral solution with the same active ingredient are not automatically pharmaceutical equivalents. Immediate-release and extended-release products differ in how drug is delivered over time. Enteric-coated and delayed-release forms can have distinct absorption. FDA assigns codes based on product-specific evidence; a generic-looking name or matching milligram amount is not enough. A product with a B code should prompt review and pharmacist attention rather than a technician’s substitution.

What the code does not decide

An Orange Book rating is not a prescription authorization and does not decide whether substitution is allowed under every state’s law. State rules can address mandatory generic substitution, prescriber “dispense as written” instructions, patient consent, notification, and records. Facility policy and payer formularies can add operational requirements. If the exact product or code is unclear, route the question to the pharmacist instead of making a substitution based on a search result alone.

A practical example

A prescription is written for a conventional immediate-release tablet. The pharmacy has a generic product with the same active ingredient, strength, dosage form, and route. The pharmacist can consult the current Orange Book to see whether FDA has assigned a therapeutic equivalence code to that product grouping, then apply state law, the prescription, and pharmacy policy. If the available product has a different release mechanism or route, a matching active ingredient does not settle equivalence.

Use the current online database

The Orange Book is updated through monthly data files and cumulative supplements. Use the current database rather than a saved screenshot or outdated printed list. Confirm the exact strength, dosage form, route, manufacturer/applicant, and code. FDA also cautions that product and reference listed drug designations can have nuance, so investigate the actual entry rather than interpreting a short code in isolation.

PTCE takeaway

Know the purpose of the Orange Book and the broad meaning of A and B. AB indicates an FDA therapeutic equivalence evaluation under the applicable grouping; it does not mean any product with the same ingredient is interchangeable. The pharmacist applies that information under state law and prescription instructions.

Operational checks that prevent mix-ups

When comparing entries, work from the product details outward instead of starting with the manufacturer name. Match active ingredient and salt, dosage form, route, and strength first. Then check the therapeutic equivalence code under the same Orange Book heading. If a candidate is extended release and the prescribed item is immediate release, the comparison stops there; a matching ingredient and dose do not make the release profiles equivalent. A “B” code also does not mean FDA has judged the product unsafe. It means therapeutic equivalence has not been established under the Orange Book framework, often because of a potential bioequivalence concern or insufficient basis. This distinction helps prevent overstatement. In routine pharmacy operations, technicians can gather the exact NDC, strength, dosage form, and manufacturer so the pharmacist can make a timely determination. A reliable answer identifies the source and date checked because monthly updates can change entries.

Scope and handoff details

The Orange Book is also not a substitution table for every product category. It focuses on approved drug products regulated through the relevant NDA and ANDA pathways. Biologics are listed in FDA’s Purple Book, and compounded preparations are not Orange Book generics. Authorized generics have a particular regulatory status and may not appear in the Orange Book as a separate ANDA product. These boundaries matter when a question uses the word “equivalent” loosely. Ask what is being compared and which FDA database evaluates it. A payer’s preferred product list may also differ from an FDA equivalence evaluation: formulary preference is a payment decision, while a TE code is FDA’s assessment of equivalence for the identified products.

Points to carry into practice

• Check the current FDA or DEA source and the pharmacy SOP for the exact requirement.
• Hold and escalate an unresolved discrepancy instead of guessing or bypassing a control.